Etarfolatide Molecular Imaging
Designed to identify tumors that may respond to folate-targeted therapy
Etarfolatide is a folate-targeted molecular imaging agent that is being developed to non-invasively identify tumors that express folate receptors and that may respond to folate-targeted therapy. It is being developed as the companion imaging agent to EC2629 (folate receptor-targeted pro-PBD).
Etarfolatide imaging has been a component of more than 20 clinical studies in patients with cancers of the ovary, endometrium, kidney, pituitary, lung, and refractory solid tumors; and has been administered to more than 1400 patients.